However, IHC still raises controversy due to the subjective assessment of the pathologist, which makes it ambiguous, and intratumoral heterogeneity leading to unprecise recommendations for BC classification (i.e., no recommended cutoff for Ki-67 in ESMO guidelines). Here, MKI67 is linked to breast cancer.